A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq® (nolatrexed dihydrochloride) given by 10-day oral administration (1999)

Author(s): Jodrell, D., Bowman, A., Rye, R., Byrne, B., Boddy, A. V., Rafi, I., Taylor, G., Johnston, A., Clendeninn, N.

      • Journal: British Journal of Cancer
      • Volume: 79
      • Issue: 5/6
      • Pages: 915-920
      • Publication type: Article
      • Bibliographic status: Published